Global Journal of Biomedical Sciences and Pharmacology

Mitochondrial Dysfunction as a Molecular Target for Novel Therapeutic Strategies in Human Disease Treatment

Dr. Olivia Martinez — 2026-06-06

Mitochondria are essential cellular organelles responsible for energy production, metabolic regulation, calcium homeostasis, and control of programmed cell death. Beyond their traditional role as energy-generating structures, mitochondria function as complex signalling platforms that regulate multiple physiological and pathological processes. Disruption of mitochondrial structure and function, commonly referred to as mitochondrial dysfunction, has been increasingly recognized as a critical contributor to the development and progression of various human diseases, including cancer, neurodegenerative disorders, cardiovascular diseases, metabolic syndromes, and inflammatory conditions.

Mitochondrial dysfunction is characterized by impaired oxidative phosphorylation, excessive production of reactive oxygen species, altered mitochondrial dynamics, defective quality control mechanisms, and disturbances in cellular metabolism. These abnormalities can promote cellular damage, inflammation, impaired energy balance, and disease progression. As a result, mitochondria have emerged as promising molecular targets for developing novel therapeutic strategies aimed at restoring cellular function and improving disease outcomes.

This review discusses the fundamental biological functions of mitochondria and examines the molecular mechanisms involved in mitochondrial dysfunction. It further explores emerging pharmacological approaches targeting mitochondrial pathways, including antioxidant therapies, mitochondrial biogenesis regulators, metabolic modulators, mitochondrial quality control enhancers, and targeted drug delivery strategies. The therapeutic potential of mitochondrial interventions in cancer, neurological disorders, cardiovascular diseases, and metabolic conditions is also evaluated.

Although mitochondrial-targeted therapies have demonstrated considerable promise, several challenges remain, including tissue-specific effects, drug delivery limitations, and the complexity of mitochondrial regulation. Advances in molecular pharmacology, nanotechnology, and precision medicine are expected to improve the development of mitochondria-focused therapeutic approaches. Understanding mitochondrial biology and its role in disease mechanisms may provide new opportunities for designing effective treatments and improving clinical outcomes.

Artificial Intelligence-Driven Drug Discovery: Transforming Pharmacological Research and Therapeutic Development Dr. Michael Anderson

Dr. Michael Anderson — 2026-06-04

Artificial Intelligence (AI) has emerged as a transformative technology in pharmaceutical research by providing advanced computational approaches for accelerating drug discovery, improving molecular prediction, and optimizing therapeutic development processes. Conventional drug discovery approaches are often associated with prolonged development timelines, high financial costs, and significant failure rates during clinical evaluation. The integration of artificial intelligence, machine learning, and deep learning techniques has introduced new opportunities for improving efficiency, reducing experimental limitations, and enabling data-driven decision-making throughout the pharmaceutical development pipeline.

AI-driven drug discovery utilizes computational algorithms to analyse complex biological datasets, identify potential therapeutic targets, predict molecular interactions, optimize drug candidates, and support personalized treatment strategies. Machine learning models can evaluate chemical structures, biological pathways, and clinical information to predict drug efficacy, toxicity, and pharmacokinetic properties. Furthermore, AI-based approaches have contributed to drug repurposing by identifying new therapeutic applications for existing compounds and reducing the time required for drug development.

This review discusses the fundamental principles of artificial intelligence applications in pharmacological research and examines its role in different stages of drug discovery, including target identification, molecular screening, lead optimization, toxicity prediction, and clinical development. The article further explores the applications of AI-driven approaches in cancer therapeutics, infectious diseases, neurological disorders, and precision medicine. The challenges associated with AI implementation, including data quality, algorithm transparency, regulatory concerns, and computational limitations, are also discussed.

Although artificial intelligence cannot replace experimental validation and clinical expertise, its integration with traditional pharmaceutical research methods provides a powerful framework for improving drug development efficiency. Future advancements in AI technologies, combined with high-quality biological datasets and interdisciplinary collaboration, may significantly enhance the discovery of safer, more effective, and personalized therapeutic interventions.

Microbiome–Drug Interactions: Emerging Insights into Therapeutic Response and Personalized Pharmacological Strategies

Dr. Emily Carter — 2026-06-24

The human microbiome has emerged as a critical biological factor influencing drug response,
therapeutic effectiveness, and individual variability in pharmacological outcomes.
Traditionally, drug metabolism and therapeutic response have been primarily associated with
host genetic factors and physiological characteristics; however, increasing evidence indicates
that microbial communities residing within the human body, particularly the intestinal
microbiota, play an essential role in modifying drug activity through complex biochemical
interactions. Microorganisms can directly metabolize pharmaceutical compounds, alter drug
bioavailability, influence pharmacokinetic profiles, and regulate host metabolic pathways
associated with therapeutic response.
Microbiome–drug interactions represent a rapidly expanding area of biomedical research with
significant implications for personalized medicine. Variations in microbial composition
among individuals may contribute to differences in treatment efficacy, drug toxicity, and
adverse reactions, creating new opportunities for microbiome-guided therapeutic strategies.
Understanding these interactions may support the development of predictive approaches that
integrate microbial characteristics with conventional pharmacological parameters for
optimized treatment selection.
This review discusses the fundamental mechanisms involved in microbiome-mediated drug
interactions, including microbial enzymatic transformation, metabolic regulation, and
host–microbe communication pathways. It further examines the influence of gut microbiota
on pharmacokinetics and pharmacodynamics, with emphasis on personalized
pharmacological approaches. The article also highlights current clinical applications,
challenges associated with microbiome-based therapeutic development, and future
opportunities for integrating microbiome analysis into precision healthcare.
Although microbiome-based pharmacology is still developing, advances in sequencing
technologies, computational biology, and systems-level analysis are improving the understanding of microbial contributions to drug response. The integration of microbiome
science with pharmacological research may provide innovative strategies for improving
therapeutic outcomes and developing individualized treatment approaches.

Organoid Technology in Biomedical Research: Advancing Disease Modeling and Drug Screening Approaches

Dr. Sophia Williams — 2026-06-05

Organoid technology has emerged as an innovative advancement in biomedical research by providing three-dimensional, self-organizing cellular models that closely replicate the structural and functional characteristics of human tissues. Traditional experimental models, including two-dimensional cell cultures and animal models, have contributed significantly to biological understanding and therapeutic development; however, they often fail to fully represent human tissue complexity and disease-specific responses. Organoids overcome several limitations by enabling the study of human-like tissue organization, cellular interactions, and disease mechanisms under controlled laboratory conditions.

Derived primarily from stem cells or patient-specific tissues, organoids can reproduce essential features of organs such as the brain, liver, intestine, kidney, and pancreas. Their ability to maintain genetic and functional characteristics of original tissues has made them valuable platforms for disease modelling, drug discovery, toxicity assessment, and personalized medicine. Organoid-based approaches allow researchers to investigate disease progression, identify therapeutic targets, and evaluate drug responses with improved biological relevance.

This review discusses the fundamental principles of organoid development and examines their applications in biomedical research, particularly in disease modelling and pharmacological screening. The role of organoids in cancer research, genetic disorders, infectious diseases, neurological conditions, and precision therapeutics is explored. Furthermore, the advantages of organoid systems over conventional experimental approaches and their contribution to patient-specific treatment strategies are discussed.

Despite significant progress, challenges related to reproducibility, vascularization, maturation, scalability, and standardization continue to influence the broader clinical and pharmaceutical adoption of organoid technology. Future integration of organoids with

artificial intelligence, advanced imaging technologies, and high-throughput screening platforms may further enhance their potential in biomedical innovation.

Overall, organoid technology represents a powerful bridge between basic research and clinical application, offering new opportunities for understanding human diseases and accelerating the development of safer and more effective therapeutic interventions.

Exosome-Based Therapeutics: Emerging Biomedical Applications in Precision Medicine and Disease Management

Dr. Sophia Williams — 2026-06-03

Exosomes have emerged as promising nanoscale therapeutic platforms with significant potential in precision medicine, targeted drug delivery, regenerative medicine, and disease management. These naturally occurring extracellular vesicles, secreted by various cell types, contain biologically active molecules including proteins, lipids, messenger RNA, microRNA, and other regulatory components that facilitate intercellular communication. Due to their unique biological properties, including low immunogenicity, biocompatibility, and ability to transport functional molecules between cells, exosomes have gained considerable attention as advanced tools for biomedical applications.

Recent advances in molecular biology and nanomedicine have demonstrated that exosomes can serve as both therapeutic agents and delivery vehicles for improving treatment outcomes. Their ability to carry genetic materials and bioactive molecules provides opportunities for developing targeted therapeutic strategies against complex diseases, including cancer, cardiovascular disorders, neurodegenerative conditions, and inflammatory diseases. Furthermore, engineered exosomes are being investigated for enhancing drug stability, improving tissue-specific delivery, and reducing systemic toxicity associated with conventional therapeutic approaches.

This review discusses the biological characteristics, formation mechanisms, and molecular functions of exosomes, highlighting their role in maintaining cellular communication and regulating physiological processes. The article further examines the emerging applications of exosome-based therapeutics in precision medicine, including their potential use in targeted drug delivery, tissue regeneration, immunotherapy, and disease-specific treatment strategies. Current challenges related to large-scale production, isolation methods, quality control, safety assessment, and clinical translation are also discussed.

Although several technological and regulatory challenges remain, continuous advancements in biotechnology, molecular engineering, and nanomedicine are accelerating the development of exosome-based therapeutic approaches. The integration of exosome technology with personalized medicine strategies may provide innovative solutions for improving therapeutic precision, enhancing treatment effectiveness, and addressing unmet clinical needs in modern healthcare.